

## **b. Discussion and Consideration of Board Regulations Regulation Timeline**

### **5. Board-Approved Regulations – Withdrawn**

- i. California Code of Regulations, Title 16, Section 1746.6, Medication Assisted Treatment Protocol

#### **Timeline:**

Approved by Board: February 7, 2023

45-Day Comment Period: June 20, 2025 – August 4, 2025

Withdrawn: February 20, 2026

**NOTICE OF DECISION NOT TO PROCEED  
Pursuant to Government Code section 11347**

**Board of Pharmacy**

**Re: Notice of Proposed Rulemaking concerning  
Medication-Assisted Treatment Protocol**

Pursuant to Government Code Section 11347, the California Board of Pharmacy (Board) hereby gives notice that it has decided not to proceed with the rulemaking action published in the California Regulatory Notice Register on June 20, 2025, Register 2025, No. 25-Z. The proposed rulemaking concerned Medication-Assisted Treatment Protocol (OAL Notice Z2025-0610-03).

Following the passage of AB 1503 (Berman, Chapter 196, Statutes of 2025), which went into effect January 1, 2026, establishing a Medication-Assisted Treatment Protocol in regulation is unnecessary due to the transition of pharmacy practice to a standard of care practice model.

Any interested person with questions concerning this rulemaking should contact Debbie Damoth at the Board of Pharmacy at 916-518-3090 or by e-mail at: [PharmacyRulemaking@dca.ca.gov](mailto:PharmacyRulemaking@dca.ca.gov).

The Board will also post this Notice of Decision Not to Proceed on its website at [https://pharmacy.ca.gov/laws\\_regs/withdrawn\\_regs.shtml](https://pharmacy.ca.gov/laws_regs/withdrawn_regs.shtml).

**DEPARTMENT OF CONSUMER AFFAIRS  
Title 16. Board of Pharmacy**

**Proposed Regulatory Language  
Medication-Assisted Treatment**

**Proposal to Add CCR section 1746.6 to Division 17 of Title 16 of the California Code of Regulations to read as follows:**

**§ 1746.6. Pharmacist-Provided Medication-Assisted Treatment**

- (a) For purposes of this section, medication-assisted treatment includes all medication used to treat a substance use disorder.
- (b) A pharmacist may initiate, modify, administer, or discontinue medication-assisted treatment pursuant to Business and Professions Code section 4052(a)(14), consistent with all relevant provisions of federal law, and shall satisfy the requirements of this section.
  - (1) The pharmacist shall possess appropriate education and training to provide medication-assisted treatment consistent with the established standard of care used by other health care practitioners providing medication-assisted treatment, including nationally accepted guidelines.
  - (2) The pharmacist shall ensure a confidential patient care area is used to provide the services. The patient may not waive consultation.
  - (3) The pharmacist shall assess the patient for signs and symptoms of substance abuse disorder through patient interview, physical assessment, and laboratory findings. This initial assessment may be waived if the patient is referred to the pharmacist for treatment following diagnosis by another health care provider.
  - (4) The pharmacist shall develop a treatment plan for a patient's substance use disorder, which may include referral to medical services, case management, psychosocial services, substance use counseling, or residential treatment.
  - (5) The pharmacist shall document the assessment, clinical findings, plan of care, and medications dispensed and administered in a patient record system and share this information with a patient's primary care provider or other prescriber, if one is identified.
  - (6) A pharmacist performing the functions authorized in this section shall do so in collaboration with other health care providers.

NOTE: Authority cited: Section 4052, Business and Professions Code. Reference: Section 4052, Business and Professions Code.